Want to see TSE:ARCH full AI Analyst Report?
Top Page
Arch Biopartners
(ARCH)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.99
▼(-3.98% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance (no TTM revenue, ongoing losses and cash burn, and negative equity with a thin asset base). Technicals are mixed-to-neutral and provide only modest support. Valuation is difficult to justify given the negative P/E and lack of dividend yield data.
Positive Factors
Focused clinical pipeline
A focused therapeutic strategy can concentrate limited resources on a clearly defined medical need. Arch Biopartners’ emphasis on inflammatory and ischemia-reperfusion injury provides a coherent development direction, with acute kidney injury offering an initial target area for clinical progress.
Negative Factors
No current revenue and ongoing losses
The absence of TTM revenue and repeated annual losses show that the business has not yet converted its development programs into commercial income. This limits internal funding capacity and leaves future progress dependent on successful development, commercialization, or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical pipeline
A focused therapeutic strategy can concentrate limited resources on a clearly defined medical need. Arch Biopartners’ emphasis on inflammatory and ischemia-reperfusion injury provides a coherent development direction, with acute kidney injury offering an initial target area for clinical progress.
Read all positive factors
Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$69.29M
Dividend YieldN/A
Average Volume (3M)54.30K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS Growth-15.53%
CountryCA
Employees6
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume60,526
30 Day Avg. Volume54,296
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Arch Biopartners Business Overview & Revenue Model
Company Description
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to addr...
Arch Biopartners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 2.12M | 1.98M | 964.68K | 3.89M |
| Gross Profit | 0.00 | 0.00 | -1.66M | -129.00K | -503.00K | -150.00K |
| EBITDA | -2.58M | -1.29M | -3.53M | -336.00K | -101.00K | -77.02K |
| Net Income | -2.83M | -1.55M | -3.92M | -3.33M | -1.41M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 57.22K | 104.53K | 935.62K | 1.17M | 621.64K | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 2.91K | 2.10K | 2.97K | 831.27K | 506.35K | 448.24K |
| Total Debt | 2.73M | 2.84M | 2.77M | 5.02M | 4.41M | 5.16M |
| Total Liabilities | 4.04M | 3.99M | 5.28M | 6.68M | 5.09M | 6.55M |
| Stockholders Equity | -3.99M | -3.88M | -4.35M | -5.51M | -4.47M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -1.72M | -1.58M | -2.33M | -234.08K | -1.08M | -2.98M |
| Operating Cash Flow | -1.72M | -1.58M | -2.33M | -234.07K | -1.08M | -2.98M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.55M | 1.58M | 1.50M | 559.00K | -421.37K | 2.78M |
Arch Biopartners Technical Analysis
Neutral
1.03
Price Trends
0.95
Positive
0.72
Positive
0.85
Positive
Market Momentum
0.03
Positive
50.44
Neutral
53.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Neutral. The current price of 1.03 is below the 20-day moving average (MA) of 1.08, above the 50-day MA of 0.95, and above the 200-day MA of 0.85, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.44 is Neutral, neither overbought nor oversold. The STOCH value of 53.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ARCH.
Arch Biopartners Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | C$42.89M | -0.29 | -147.92% | ― | ― | 85.31% | |
49 Neutral | C$264.14M | -4.59 | -71.28% | ― | ― | -6.00% | |
46 Neutral | C$36.48M | -2.13 | -360.29% | ― | ― | -33.27% | |
44 Neutral | C$69.29M | -24.00 | 74.79% | ― | ― | -15.53% |
* General Sector Average
TSE:ARCH
Arch Biopartners
1.02
-0.63
-38.18%
TSE:MSCL
Satellos Bioscience
12.45
4.53
57.20%
TSE:MDNA
Medicenna Therapeutics Corp
0.47
-0.59
-55.66%
TSE:BCT
BriaCell Therapeutics
4.93
-6.05
-55.10%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-1.50
-37.50%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.